Specialized pro-resolving mediators in cardiovascular diseases

Molecular Aspects of Medicine

Volumn 58, Issue , 2017, Pages 65-71

  Fredman, Gabrielle ^a   Spite, Matthew ^b  

^a ALBANY MEDICAL COLLEGE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Atherosclerosis; Resolution of inflammation; Specialized pro resolving mediators

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ARACHIDONATE 15 LIPOXYGENASE; CD59 ANTIGEN; CELL RECEPTOR; LIPOCORTIN 1; LIPOXIN; LIPOXIN A; MARESIN; RESOLVIN; UNCLASSIFIED DRUG; AUTACOID; PEPTIDE;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DISEASE COURSE; EFFEROCYTOSIS; HEART INFARCTION; HOST RESISTANCE; HUMAN; ISCHEMIA; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REVIEW; THROMBOCYTE ACTIVATION; THROMBOSIS; ANIMAL; METABOLISM; PATHOLOGY;

ANIMALS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; HUMANS; INFLAMMATION MEDIATORS; ISCHEMIA; MYOCARDIAL INFARCTION; PEPTIDES; PLATELET ACTIVATION; THROMBOSIS;

EID: 85017092520     PISSN: 00982997     EISSN: 18729452     Source Type: Journal    
DOI: 10.1016/j.mam.2017.02.003     Document Type: Review

References (94)

1. Abdulnour, R.E., Dalli, J., Colby, J.K., Krishnamoorthy, N., Timmons, J.Y., Tan, S.H., Colas, R.A., Petasis, N.A., Serhan, C.N., Levy, B.D., Maresin 1 biosynthesis during platelet-neutrophil interactions is organ-protective. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 16526–16531.
2. Akagi, D., Chen, M., Toy, R., Chatterjee, A., Conte, M.S., Systemic delivery of proresolving lipid mediators resolvin D2 and maresin 1 attenuates intimal hyperplasia in mice. FASEB J. 29 (2015), 2504–2513.
3. Bohr, S., Patel, S.J., Sarin, D., Irimia, D., Yarmush, M.L., Berthiaume, F., Resolvin D2 prevents secondary thrombosis and necrosis in a mouse burn wound model. Wound Repair Regen. 21 (2013), 35–43.
4. Bonaca, M.P., Creager, M.A., Pharmacological treatment and current management of peripheral artery disease. Circ. Res. 116 (2015), 1579–1598.
5. Borgeson, E., Docherty, N.G., Murphy, M., Rodgers, K., Ryan, A., O'Sullivan, T.P., Guiry, P.J., Goldschmeding, R., Higgins, D.F., Godson, C., Lipoxin A(4) and benzo-lipoxin A(4) attenuate experimental renal fibrosis. FASEB J. 25 (2011), 2967–2979.
6. Brezinski, D.A., Nesto, R.W., Serhan, C.N., Angioplasty triggers intracoronary leukotrienes and lipoxin A4. Impact of aspirin therapy. Circulation 86 (1992), 56–63.
7. Cai, B., Thorp, E.B., Doran, A.C., Subramanian, M., Sansbury, B.E., Lin, C.S., Spite, M., Fredman, G., Tabas, I., MerTK cleavage limits proresolving mediator biosynthesis and exacerbates tissue inflammation. Proc. Natl. Acad. Sci. U. S. A. 113 (2016), 6526–6531.
8. Cai, B., Thorp, E.B., Doran, A.C., Sansbury, B.E., Daemen, M.J., Dorweiler, B., Spite, M., Fredman, G., Tabas, I., MerTK receptor cleavage promotes plaque necrosis and defective resolution in atherosclerosis. J. Clin. Invest 127 (2017), 564–568.
9. Cheuk, B.L., Cheng, S.W., Annexin A1 expression in atherosclerotic carotid plaques and its relationship with plaque characteristics. Eur. J. Vasc. Endovasc. Surg. 41 (2011), 364–371.
10. Chiang, N., Bermudez, E.A., Ridker, P.M., Hurwitz, S., Serhan, C.N., Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. Proc. Natl. Acad. Sci. U. S. A. 101 (2004), 15178–15183.
11. Chiang, N., Hurwitz, S., Ridker, P.M., Serhan, C.N., Aspirin has a gender-dependent impact on antiinflammatory 15-epi-lipoxin A4 formation: a randomized human trial. Arterioscler. Thromb. Vasc. Biol., 26, 2006 e14–7.
12. Chiang, N., Fredman, G., Backhed, F., Oh, S.F., Vickery, T., Schmidt, B.A., Serhan, C.N., Infection regulates pro-resolving mediators that lower antibiotic requirements. Nature 484 (2012), 524–528.
13. Chiang, N., Dalli, J., Colas, R.A., Serhan, C.N., Identification of resolvin D2 receptor mediating resolution of infections and organ protection. J. Exp. Med. 212 (2015), 1203–1217.
14. Chilian, W.M., Penn, M.S., Pung, Y.F., Dong, F., Mayorga, M., Ohanyan, V., Logan, S., Yin, L., Coronary collateral growth–back to the future. J. Mol. Cell Cardiol. 52 (2012), 905–911.
15. Chiurchiu, V., Leuti, A., Dalli, J., Jacobsson, A., Battistini, L., Maccarrone, M., Serhan, C.N., Proresolving lipid mediators resolvin D1, resolvin D2, and maresin 1 are critical in modulating T cell responses. Sci. Transl. Med., 8, 2016 353ra111.
16. Colgan, S.P., Neutrophils and inflammatory resolution in the mucosa. Semin. Immunol. 27 (2015), 177–183.
17. Cooray, S.N., Gobbetti, T., Montero-Melendez, T., McArthur, S., Thompson, D., Clark, A.J., Flower, R.J., Perretti, M., Ligand-specific conformational change of the G-protein-coupled receptor ALX/FPR2 determines proresolving functional responses. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 18232–18237.
18. Cyrus, T., Witztum, J.L., Rader, D.J., Tangirala, R., Fazio, S., Linton, M.F., Funk, C.D., Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. J. Clin. Invest 103 (1999), 1597–1604.
19. Dalli, J., Serhan, C.N., Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators. Blood 120 (2012), e60–72.
20. Dona, M., Fredman, G., Schwab, J.M., Chiang, N., Arita, M., Goodarzi, A., Cheng, G., von Andrian, U.H., Serhan, C.N., Resolvin E1, an EPA-derived mediator in whole blood, selectively counterregulates leukocytes and platelets. Blood 112 (2008), 848–855.
21. Doring, Y., Drechsler, M., Wantha, S., Kemmerich, K., Lievens, D., Vijayan, S., Gallo, R.L., Weber, C., Soehnlein, O., Lack of neutrophil-derived CRAMP reduces atherosclerosis in mice. Circ. Res. 110 (2012), 1052–1056.
22. Drechsler, M., de Jong, R., Rossaint, J., Viola, J.R., Leoni, G., Wang, J.M., Grommes, J., Hinkel, R., Kupatt, C., Weber, C., Doring, Y., Zarbock, A., Soehnlein, O., Annexin A1 counteracts chemokine-induced arterial myeloid cell recruitment. Circ. Res. 116 (2015), 827–835.
23. Duffield, J.S., Hong, S., Vaidya, V.S., Lu, Y., Fredman, G., Serhan, C.N., Bonventre, J.V., Resolvin D series and protectin D1 mitigate acute kidney injury. J. Immunol. 177 (2006), 5902–5911.
24. Dufton, N., Hannon, R., Brancaleone, V., Dalli, J., Patel, H.B., Gray, M., D'Acquisto, F., Buckingham, J.C., Perretti, M., Flower, R.J., Anti-inflammatory role of the murine formyl-peptide receptor 2: ligand-specific effects on leukocyte responses and experimental inflammation. J. Immunol. 184 (2010), 2611–2619.
25. Elajami, T.K., Colas, R.A., Dalli, J., Chiang, N., Serhan, C.N., Welty, F.K., Specialized proresolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling. FASEB J. 30 (2016), 2792–2801.
26. Everett, B.M., Pradhan, A.D., Solomon, D.H., Paynter, N., Macfadyen, J., Zaharris, E., Gupta, M., Clearfield, M., Libby, P., Hasan, A.A., Glynn, R.J., Ridker, P.M., Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am. Heart J. 166 (2013), 199–207 e15.
27. Feig, J.E., Vengrenyuk, Y., Reiser, V., Wu, C., Statnikov, A., Aliferis, C.F., Garabedian, M.J., Fisher, E.A., Puig, O., Regression of atherosclerosis is characterized by broad changes in the plaque macrophage transcriptome. PLoS One, 7, 2012 e39790.
28. Filep, J.G., Biasing the lipoxin A4/formyl peptide receptor 2 pushes inflammatory resolution. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 18033–18034.
29. Foley, J.H., Conway, E.M., Cross talk pathways between coagulation and inflammation. Circ. Res. 118 (2016), 1392–1408.
30. Fredman, G., Van Dyke, T.E., Serhan, C.N., Resolvin E1 regulates adenosine diphosphate activation of human platelets. Arterioscler. Thromb. Vasc. Biol. 30 (2010), 2005–2013.
31. Fredman, G., Ozcan, L., Spolitu, S., Hellmann, J., Spite, M., Backs, J., Tabas, I., Resolvin D1 limits 5-lipoxygenase nuclear localization and leukotriene B4 synthesis by inhibiting a calcium-activated kinase pathway. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 14530–14535.
32. Fredman, G., Kamaly, N., Spolitu, S., Milton, J., Ghorpade, D., Chiasson, R., Kuriakose, G., Perretti, M., Farokhzad, O., Tabas, I., Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice. Sci. Transl. Med., 7, 2015 275ra20.
33. Fredman, G., Hellmann, J., Proto, J.D., Kuriakose, G., Colas, R.A., Dorweiler, B., Connolly, E.S., Solomon, R., Jones, D.M., Heyer, E.J., Spite, M., Tabas, I., An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques. Nat. Commun., 7, 2016, 12859.
34. Gao, Y., Min, K., Zhang, Y., Su, J., Greenwood, M., Gronert, K., Female-specific downregulation of tissue polymorphonuclear neutrophils drives impaired regulatory T cell and amplified effector T cell responses in autoimmune dry eye disease. J. Immunol. 195 (2015), 3086–3099.
35. Gerdes, N., Seijkens, T., Lievens, D., Kuijpers, M.J., Winkels, H., Projahn, D., Hartwig, H., Beckers, L., Megens, R.T., Boon, L., Noelle, R.J., Soehnlein, O., Heemskerk, J.W., Weber, C., Lutgens, E., Platelet CD40 exacerbates atherosclerosis by transcellular activation of endothelial cells and leukocytes. Arterioscler. Thromb. Vasc. Biol. 36 (2016), 482–490.
36. Glass, C.K., Natoli, G., Molecular control of activation and priming in macrophages. Nat. Immunol. 17 (2016), 26–33.
37. Hasturk, H., Kantarci, A., Goguet-Surmenian, E., Blackwood, A., Andry, C., Serhan, C.N., Van Dyke, T.E., Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo. J. Immunol. 179 (2007), 7021–7029.
38. Hasturk, H., Abdallah, R., Kantarci, A., Nguyen, D., Giordano, N., Hamilton, J., Van Dyke, T.E., Resolvin E1 (RvE1) attenuates atherosclerotic plaque formation in diet and inflammation-induced atherogenesis. Arterioscler. Thromb. Vasc. Biol. 35 (2015), 1123–1133.
39. Horckmans, M., Ring, L., Duchene, J., Santovito, D., Schloss, M.J., Drechsler, M., Weber, C., Soehnlein, O., Steffens, S., Neutrophils orchestrate post-myocardial infarction healing by polarizing macrophages towards a reparative phenotype. Eur. Heart J., 2016.
40. Howangyin, K.Y., Zlatanova, I., Pinto, C., Ngkelo, A., Cochain, C., Rouanet, M., Vilar, J., Lemitre, M., Stockmann, C., Fleischmann, B.K., Mallat, Z., Silvestre, J.S., Myeloid-Epithelial-Reproductive receptor tyrosine kinase and milk fat globule epidermal growth factor 8 coordinately improve remodeling after myocardial infarction via local delivery of vascular endothelial growth factor. Circulation 133 (2016), 826–839.
41. Huynh, M.L., Fadok, V.A., Henson, P.M., Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. J. Clin. Invest 109 (2002), 41–50.
42. Kain, V., Ingle, K.A., Colas, R.A., Dalli, J., Prabhu, S.D., Serhan, C.N., Joshi, M., Halade, G.V., Resolvin D1 activates the inflammation resolving response at splenic and ventricular site following myocardial infarction leading to improved ventricular function. J. Mol. Cell Cardiol. 84 (2015), 24–35.
43. Kamaly, N., Fredman, G., Fojas, J.J., Subramanian, M., Choi, W.I., Zepeda, K., Vilos, C., Yu, M., Gadde, S., Wu, J., Milton, J., Carvalho Leitao, R., Rosa Fernandes, L., Hasan, M., Gao, H., Nguyen, V., Harris, J., Tabas, I., Farokhzad, O.C., Targeted Interleukin-10 nanotherapeutics developed with a microfluidic chip enhance resolution of inflammation in advanced atherosclerosis. ACS Nano 10 (2016), 5280–5292.
44. Kasuga, K., Yang, R., Porter, T.F., Agrawal, N., Petasis, N.A., Irimia, D., Toner, M., Serhan, C.N., Rapid appearance of resolvin precursors in inflammatory exudates: novel mechanisms in resolution. J. Immunol. 181 (2008), 8677–8687.
45. Keyes, K.T., Ye, Y., Lin, Y., Zhang, C., Perez-Polo, J.R., Gjorstrup, P., Birnbaum, Y., Resolvin E1 protects the rat heart against reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 299 (2010), H153–H164.
46. Kojima, Y., Volkmer, J.P., McKenna, K., Civelek, M., Lusis, A.J., Miller, C.L., Direnzo, D., Nanda, V., Ye, J., Connolly, A.J., Schadt, E.E., Quertermous, T., Betancur, P., Maegdefessel, L., Matic, L.P., Hedin, U., Weissman, I.L., Leeper, N.J., CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature 536 (2016), 86–90.
47. Kumar, V., Abbas, A.K., Fausto, N., Robbins, S.L., Cotran, R.S., Robbins and Cotran Pathologic Basis of Disease. seventh ed., 2005, Elsevier/Saunders, Philadelphia.
48. Kusters, D.H., Chatrou, M.L., Willems, B.A., De Saint-Hubert, M., Bauwens, M., van der Vorst, E., Bena, S., Biessen, E.A., Perretti, M., Schurgers, L.J., Reutelingsperger, C.P., Pharmacological treatment with Annexin A1 reduces atherosclerotic plaque burden in LDLR-/- mice on western type diet. PLoS One, 10, 2015 e0130484.
49. Lance, K.D., Chatterjee, A., Wu, B., Mottola, G., Nuhn, H., Lee, P.P., Sansbury, B.E., Spite, M., Desai, T.A., Conte, M.S., Unidirectional and sustained delivery of the proresolving lipid mediator resolvin D1 from a biodegradable thin film device. J. Biomed. Mater Res. A 105 (2017), 31–41.
50. Lannan, K.L., Spinelli, S.L., Blumberg, N., Phipps, R.P., Maresin 1 induces a novel pro-resolving phenotype in human platelets. J. Thromb. Haemost., 2017.
51. Lee, H.N., Surh, Y.J., Resolvin D1-mediated NOX2 inactivation rescues macrophages undertaking efferocytosis from oxidative stress-induced apoptosis. Biochem. Pharmacol. 86 (2013), 759–769.
52. Li, S., Sun, Y., Liang, C.P., Thorp, E.B., Han, S., Jehle, A.W., Saraswathi, V., Pridgen, B., Kanter, J.E., Li, R., Welch, C.L., Hasty, A.H., Bornfeldt, K.E., Breslow, J.L., Tabas, I., Tall, A.R., Defective phagocytosis of apoptotic cells by macrophages in atherosclerotic lesions of ob/ob mice and reversal by a fish oil diet. Circ. Res. 105 (2009), 1072–1082.
53. Libby, P., Ridker, P.M., Maseri, A., Inflammation and atherosclerosis. Circulation 105 (2002), 1135–1143.
54. Libby, P., Tabas, I., Fredman, G., Fisher, E.A., Inflammation and its resolution as determinants of acute coronary syndromes. Circ. Res. 114 (2014), 1867–1879.
55. Merched, A.J., Ko, K., Gotlinger, K.H., Serhan, C.N., Chan, L., Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J. 22 (2008), 3595–3606.
56. Merched, A.J., Serhan, C.N., Chan, L., Nutrigenetic disruption of inflammation-resolution homeostasis and atherogenesis. J. Nutr. Nutr. 4 (2011), 12–24.
57. Miyahara, T., Runge, S., Chatterjee, A., Chen, M., Mottola, G., Fitzgerald, J.M., Serhan, C.N., Conte, M.S., D-series resolvin attenuates vascular smooth muscle cell activation and neointimal hyperplasia following vascular injury. FASEB J. 27 (2013), 2220–2232.
58. Moore, K.J., Tabas, I., Macrophages in the pathogenesis of atherosclerosis. Cell 145 (2011), 341–355.
59. Moore, K.J., Sheedy, F.J., Fisher, E.A., Macrophages in atherosclerosis: a dynamic balance. Nat. Rev. Immunol. 13 (2013), 709–721.
60. Morita, M., Kuba, K., Ichikawa, A., Nakayama, M., Katahira, J., Iwamoto, R., Watanebe, T., Sakabe, S., Daidoji, T., Nakamura, S., Kadowaki, A., Ohto, T., Nakanishi, H., Taguchi, R., Nakaya, T., Murakami, M., Yoneda, Y., Arai, H., Kawaoka, Y., Penninger, J.M., Arita, M., Imai, Y., The lipid mediator protectin D1 inhibits influenza virus replication and improves severe influenza. Cell 153 (2013), 112–125.
61. Norling, L.V., Spite, M., Yang, R., Flower, R.J., Perretti, M., Serhan, C.N., Cutting edge: humanized nano-proresolving medicines mimic inflammation-resolution and enhance wound healing. J. Immunol. 186 (2011), 5543–5547.
62. Norling, L.V., Headland, S.E., Dalli, J., Arnardottir, H.H., Haworth, O., Jones, H.R., Irimia, D., Serhan, C.N., Perretti, M., Proresolving and cartilage-protective actions of resolvin D1 in inflammatory arthritis. JCI Insight, 1, 2016, e85922.
63. Norris, P.C., Arnardottir, H., Sanger, J.M., Fichtner, D., Keyes, G.S., Serhan, C.N., Resolvin D3 multi-level proresolving actions are host protective during infection. Prostagl. Leukot. Essent. Fat. Acids, 2016.
64. Perretti, M., Leroy, X., Bland, E.J., Montero-Melendez, T., Resolution pharmacology: opportunities for therapeutic innovation in inflammation. Trends Pharmacol. Sci. 36 (2015), 737–755.
65. Petri, M.H., Laguna-Fernandez, A., Tseng, C.N., Hedin, U., Perretti, M., Back, M., Aspirin-triggered 15-epi-lipoxin A(4) signals through FPR2/ALX in vascular smooth muscle cells and protects against intimal hyperplasia after carotid ligation. Int. J. Cardiol. 179 (2015), 370–372.
66. Petri, M.H., Laguna-Fernandez, A., Arnardottir, H., Wheelock, C.E., Perretti, M., Hansson, G.K., Back, M., Aspirin-triggered lipoxin inhibits atherosclerosis progression in ApoE-/- mice. Br. J. Pharmacol., 2017.
67. Poeckel, D., Funk, C.D., The 5-lipoxygenase/leukotriene pathway in preclinical models of cardiovascular disease. Cardiovasc Res. 86 (2010), 243–253.
68. Ridker, P.M., Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). J. Thromb. Haemost. 7:Suppl. 1 (2009), 332–339.
69. Ridker, P.M., Howard, C.P., Walter, V., Everett, B., Libby, P., Hensen, J., Thuren, T., Group, C.P.I., Effects of interleukin-1beta inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation 126 (2012), 2739–2748.
70. Ross, R., Rous-Whipple Award Lecture. Atherosclerosis: a defense mechanism gone awry. Am. J. Pathol. 143 (1993), 987–1002.
71. Ross, R., Glomset, J., Harker, L., Response to injury and atherogenesis. Am. J. Pathol. 86 (1977), 675–684.
72. Salic, K., Morrison, M.C., Verschuren, L., Wielinga, P.Y., Wu, L., Kleemann, R., Gjorstrup, P., Kooistra, T., Resolvin E1 attenuates atherosclerosis in absence of cholesterol-lowering effects and on top of atorvastatin. Atherosclerosis 250 (2016), 158–165.
73. Schrijvers, D.M., De Meyer, G.R., Kockx, M.M., Herman, A.G., Martinet, W., Phagocytosis of apoptotic cells by macrophages is impaired in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 25 (2005), 1256–1261.
74. Schwab, J.M., Chiang, N., Arita, M., Serhan, C.N., Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 447 (2007), 869–874.
75. Serhan, C.N., Pro-resolving lipid mediators are leads for resolution physiology. Nature 510 (2014), 92–101.
76. Serhan, C.N., Jain, A., Marleau, S., Clish, C., Kantarci, A., Behbehani, B., Colgan, S.P., Stahl, G.L., Merched, A., Petasis, N.A., Chan, L., Van Dyke, T.E., Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators. J. Immunol. 171 (2003), 6856–6865.
77. Shapiro, M.D., Fazio, S., From lipids to inflammation: new approaches to reducing atherosclerotic risk. Circ. Res. 118 (2016), 732–749.
78. Shen, J., Herderick, E., Cornhill, J.F., Zsigmond, E., Kim, H.S., Kuhn, H., Guevara, N.V., Chan, L., Macrophage-mediated 15-lipoxygenase expression protects against atherosclerosis development. J. Clin. Invest 98 (1996), 2201–2208.
79. Shinohara, M., Serhan, C.N., Novel endogenous proresolving molecules:essential fatty acid-derived and gaseous mediators in the resolution of inflammation. J. Atheroscler. Thromb. 23 (2016), 655–664.
80. Spite, M., Claria, J., Serhan, C.N., Resolvins, specialized proresolving lipid mediators, and their potential roles in metabolic diseases. Cell Metab. 19 (2014), 21–36.
81. Swirski, F.K., Nahrendorf, M., Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science 339 (2013), 161–166.
82. Tabas, I., Macrophage death and defective inflammation resolution in atherosclerosis. Nat. Rev. Immunol. 10 (2010), 36–46.
83. Tabas, I., Bornfeldt, K.E., Macrophage phenotype and function in different stages of atherosclerosis. Circ. Res. 118 (2016), 653–667.
84. Tonetti, M.S., Van Dyke TE and working group 1 of the joint EFPAAPw. Periodontitis and atherosclerotic cardiovascular disease: consensus report of the joint EFP/AAP workshop on Periodontitis and systemic diseases. J. Periodontol. 84 (2013), S24–S29.
85. Vartanian, S.M., Conte, M.S., Surgical intervention for peripheral arterial disease. Circ. Res. 116 (2015), 1614–1628.
86. Viiri, L.E., Full, L.E., Navin, T.J., Begum, S., Didangelos, A., Astola, N., Berge, R.K., Seppala, I., Shalhoub, J., Franklin, I.J., Perretti, M., Lehtimaki, T., Davies, A.H., Wait, R., Monaco, C., Smooth muscle cells in human atherosclerosis: proteomic profiling reveals differences in expression of Annexin A1 and mitochondrial proteins in carotid disease. J. Mol. Cell Cardiol. 54 (2013), 65–72.
87. Viola, J.R., Lemnitzer, P., Jansen, Y., Csaba, G., Winter, C., Neideck, C., Silvestre-Roig, C., Dittmar, G., Doring, Y., Drechsler, M., Weber, C., Zimmer, R., Cenac, N., Soehnlein, O., Resolving lipid mediators maresin 1 and resolvin D2 prevent atheroprogression in mice. Circ. Res. 119 (2016), 1030–1038.
88. Virmani, R., Burke, A.P., Farb, A., Kolodgie, F.D., Pathology of the vulnerable plaque. J. Am. Coll. Cardiol. 47 (2006), C13–C18.
89. Wallace, J.L., Ianaro, A., Flannigan, K.L., Cirino, G., Gaseous mediators in resolution of inflammation. Semin. Immunol. 27 (2015), 227–233.
90. Wan, E., Yeap, X.Y., Dehn, S., Terry, R., Novak, M., Zhang, S., Iwata, S., Han, X., Homma, S., Drosatos, K., Lomasney, J., Engman, D.M., Miller, S.D., Vaughan, D.E., Morrow, J.P., Kishore, R., Thorp, E.B., Enhanced efferocytosis of apoptotic cardiomyocytes through myeloid-epithelial-reproductive tyrosine kinase links acute inflammation resolution to cardiac repair after infarction. Circ. Res. 113 (2013), 1004–1012.
91. Williams, K.J., Tabas, I., The response-to-retention hypothesis of early atherogenesis. Arterioscler. Thromb. Vasc. Biol. 15 (1995), 551–561.
92. Wu, B., Mottola, G., Chatterjee, A., Lance, K.D., Chen, M., Siguenza, I.O., Desai, T.A., Conte, M.S., Perivascular delivery of resolvin D1 inhibits neointimal hyperplasia in a rat model of arterial injury. J. Vasc. Surg. 65 (2017), 207–217 e3.
93. Yatomi, M., Hisada, T., Ishizuka, T., Koga, Y., Ono, A., Kamide, Y., Seki, K., Aoki-Saito, H., Tsurumaki, H., Sunaga, N., Kaira, K., Dobashi, K., Yamada, M., Okajima, F., 17(R)-resolvin D1 ameliorates bleomycin-induced pulmonary fibrosis in mice. Physiol. Rep., 2015, 3.
94. Zhang, M.J., Sansbury, B.E., Hellmann, J., Baker, J.F., Guo, L., Parmer, C.M., Prenner, J.C., Conklin, D.J., Bhatnagar, A., Creager, M.A., Spite, M., Resolvin D2 enhances postischemic revascularization while resolving inflammation. Circulation 134 (2016), 666–680.